Disease Info Card

Monocytic Leukemia

Information about Monocytic Leukemia: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Monocytic Leukemia

Most recent studies have shown that Monocytic Leukemia shares some biological mechanisms with acute-leukemia, acute-lymphocytic-leukemia, acute-monocytic-leukemia, acute-myelomonocytic-leukemia, acute-promyelocytic-leukemia, anemia, carcinoma, chronic-monocytic-leukemia, cytogenetic-abnormality, inflammation, leukemia, leukemia-myelocytic-acute, lymphoid-leukemia, lymphoma, malignant-neoplasms, malignant-paraganglionic-neoplasm, myeloid-leukemia, myeloid-leukemia-chronic, myelomonocytic-leukemia, neoplasms.

Among the many pathways, these few ones have gauged particular interests from scientists studying Monocytic Leukemia, and have been seen in publications frequently: Cell Adhesion, Cell Cycle, Cell Cycle Arrest, Cell Death, Cell Differentiation, Cell Growth, Cell Proliferation, Chemotaxis, Coagulation, Immune Response, Induction Of Apoptosis, Localization, Macrophage Differentiation, Pathogenesis, Phagocytosis, Reverse Transcription, S Phase, Secretion, Sensitization, Transport

Quite a number of genes have been found to play important roles in Monocytic Leukemia, such as CASP3, CCL2, CD14, CDKN1A, CTLA4, F3, FANCB, HLA-DQA1, IFNG, IL1B, IL6, JUN, KAT6A, LYZ, NDUFA2, NOD2, TLR4, TNF. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.